Living longer with pancreatic cancer: More than FOLFIRINOX?

476 Background: Effective treatment for uresectable locally advanced pancreatic cancer (LAPC) or metastatic pancreatic cancer is limited and has a poor prognosis with a five year survival rate of 6.7%. FOLFIRINOX has been studied as a neoadjuvant therapy for LAPC and has a response rate of 32%. We set out to investigate which factors, if any, have a meaningful impact on time to disease progression within this cohort of patients. Methods: A retrospective chart review was conducted. All patients who recieved FOLFIRINOX at our institution from 2011-2014 were included. 16 of 19 had unresectable LAPC or metastatic disease at time of diagnosis. A few recieved FOLFIRINOX upon first progression after adjuvant therapy. Results: See Table. Conclusions: Novel approaches are being used to get patients to R0 resection if they have borderline resectable pancreatic cancer or unresectable LAPC consisting of combination chemotherapy followed by radiation. Metastatic patients or unresectable LAPC who do not undergo surgery...